HIV Sequence Databases

Carla Kuiken

Bette Korber

Robert Shafer

^{Los Alamos National Laboratory, Los Alamos, New Mexico, USA}

^{Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA, USA}

Correspondence to: Carla Kuiken, Los Alamos National Laboratory, Los Alamos, NM 87545, USA, E-mail: vog.lnal@nekiuk

Abstract

Two important databases are often used in HIV genetic research, the HIV Sequence Database in Los Alamos, which collects all sequences and focuses on annotation and data analysis, and the HIV RT/Protease Sequence Database in Stanford, which collects sequences associated with the development of viral resistance against anti-retroviral drugs and focuses on analysis of those sequences. The types of data and services these two databases offer, the tools they provide, and the way they are set up and operated are described in detail.

Keywords: HIV, Database, Analysis, Resistance, Genetic sequences, Evolution

Abstract

References

1. Robertson D, Gao F, Hahn HB, Sharp P. Intersubtype recombinant HIV-1 sequences. In: Korber B, Hahn B, Foley B, et al., editors. Human Retroviruses and AIDS 1997. Los Alamos: Los Alamos National Laboratory; 1997. [PubMed]
2. Kuiken C, Korber B. Sequence quality control. In: Korber B, Kuiken CL, Foley B, et al., editors. Human Retroviruses and AIDS 1998. Los Alamos: Los Alamos National Laboratory; 1998. [PubMed]
3. Siepel A, Halpern A, Macken C, Korber BA computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses. 1995;11:1413–1416.[PubMed][Google Scholar]
4. Korber B, Foley B, Kuiken C, Pillai S, Sodroski J. Numbering Positions in HIV Relative to HXB2CG. In: Korber B, Kuiken C, Foley B, et al., editors. Human Retroviruses and AIDS. Los Alamos: Los Alamos National Laboratory; 1998. [PubMed]
5. Robertson D, Bradac J, Foley B, et al HIV-1 nomenclature proposal. Science. 2000:5463.[PubMed][Google Scholar]
6. Parikh U, Hammond J, Calef C, Larder B, Schinazi R, Mellors J. Mutations in retroviral genes associated with drug resistance. In: Kuiken C, Foley B, Hahn B, et al., editors. HIV Sequence Compendium. Los Alamos NM: Los Alamos National Laboratory; 2001. [PubMed]
7. Cormier E, Dragic T. An overview of HIV-1 coreceptor function and its inhibitors. In: Kuiken C, Foley B, Hahn B, et al., editors. HIV Sequence Compendium. Los Alamos, NM: Los Alamos National Laboratory; 2000. [PubMed]
8. Gaschen B, Taylor J, Yusim K, et al Diversity considerations in HIV-1 vaccine selection. Science. 2002;296:2354–2360.[PubMed][Google Scholar]
9. Warren J, Levinson MFourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. J Med Primatol. 1995;24:150–168.[PubMed][Google Scholar]
10. Sharp P, Bailes E, Robertson D, Gao F, Hahn BOrigins and evolution of AIDS viruses. Biol Bull. 1999;196:338–342.[PubMed][Google Scholar]
11. Hahn B, Shaw G, De Cock K, Sharp PAIDS as a zoonosis: scientific and public health implications. Science. 2000;287:607–614.[PubMed][Google Scholar]
12. Chen Z, Luckay A, Sodora D, et al HIV-2 seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J Virol. 1997;71:3953–3960.[Google Scholar]
13. Gao F, Robertson D, Morrison S, et al The heterosexual HIV type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol. 1996;70:7013–7029.[Google Scholar]
14. Carr J, Salminen M, Koch C, et al Full-length sequence and mosaic structure of a HIV type 1 isolate from Thailand. J Virol. 1996;70:5935–5943.[Google Scholar]
15. Gaschen B, Kuiken C, Korber B, Foley BRetrieval and on-the-fly alignment of sequence fragments from the HIV data-base. Bioinformatics. 2001;17:415–418.[PubMed][Google Scholar]
16. Yang Z, Nielsen R, Hasegawa MModels of amino acid substitution and applications to mitochondrial protein evolution. Mol Biol Evol. 1998;15:1600–1611.[PubMed][Google Scholar]
17. Rose P, Korber BDetecting hypermutations in viral sequences with an emphasis on G —> A hypermutation. Bioinformatics. 2000;16:400–401.[PubMed][Google Scholar]
18. Calef C. Numbering positions in SIV relative to SIVMM239. In: Kuiken C, Foley B, Hahn B, et al., editors. Human Retroviruses and AIDS. Los Alamos: Los Alamos National Laboratory; 2001. [PubMed]
19. Higgins DSequence ordinations: a multivariate analysis approach to analysing large sequence data sets. Comput Appl Biosci. 1992;8:15–22.[PubMed][Google Scholar]
20. Delwart E, Gordon CTracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods. 1997;12:348–354.[PubMed][Google Scholar]
21. Hirsch M, Brun-Vezinet F, D’Aquila R, et al Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000;283:2417–2426.[PubMed][Google Scholar]
22. Demeter L, Haubrich RPhenotypic and genotypic resistance assays: methodology, reliability, and interpretations. J Acquir Immune Defic Syndr. 2001;26 Suppl 1:3–9.[PubMed][Google Scholar]
23. Haubrich R, Demeter LClinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr. 2001;26 Suppl 1:51–59.[PubMed][Google Scholar]
24. Miller V, Larder BMutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther. 2001;6 Suppl 3:25–44.[PubMed][Google Scholar]
25. Miller VResistance to protease inhibitors. J Acquir Immune Defic Syndr. 2001;26 Suppl 1:34–50.[PubMed][Google Scholar]
26. Hanna G, D’Aquila RClinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis. 2001;32:774–782.[PubMed][Google Scholar]
27. Shafer RGenotypic testing for HIV type 1 drug resistance. Clin Microbiol Rev. 2002;15:247–277.[Google Scholar]
28. Kantor R, Machekano R, Gonzales M, Dupnik B, Schapiro J, Shafer RHIV reverse transcriptase and protease sequence database: An expanded model integrating natural language text sequence analysis. Nucleic Acids Res. 2001;29:296–299.[Google Scholar]
29. Gonzales M, Dugan J, Shafer RSynonymous-non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN) Bioinformatics. 2002;18:886–887.[Google Scholar]
30. Shafer R, Jung D, Betts BHIV type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med. 2000;6:1290–1292.[Google Scholar]
31. Kilby J, Hopkins S, Venetta T, et al Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4:1302–1307.[PubMed][Google Scholar]
32. Clotet B, Lazzarin A, Cooper D, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals in Europe and Australia; World AIDS Conference; Barcelona. 2002. [LbOr19A] [PubMed]
33. Henry K, Lalezari J, O’Hearn M, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three drug classes of approved antiretrovirals in North America and Brazil; World AIDS Conference; Barcelona. 2002. [LbOr19B] [PubMed]
34. Kantor R, Katzenstein D, Gonzales M, et al Influence of subtype and treatment on genetic profiles for HIV-1 reverse transcriptase and protease: do they act independently in predicting mutation specific probabilities in non-subtype B sequences. Antivir Ther. 2002;7 Suppl:142.[PubMed][Google Scholar]
35. UK Collaborative Group on Monitoring the Transmission of HIV Drug ResistanceAnalysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ. 2001;322:1087–1088.[Google Scholar]
36. Simon V, Vanderhoeven J, Hurley A, et al Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS. 2002;16:1511–1519.[PubMed][Google Scholar]
37. Grant R, Hecht F, Warmerdam M, et al Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288:181–188.[PubMed][Google Scholar]
38. Little S, Holte S, Routy J, et al Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385–394.[PubMed][Google Scholar]
39. Gonzales MJ, Machekano R, Shafer RHIV type 1 reverse transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis. 2001;184:998–1006.[Google Scholar]
40. Schiffer C, Scott W, Stewart F, King M, Kempf DThe uncommon HIV-1 protease mutation I54T is highly associated with G48V and may affect cleavage dynamics by stabilizing the structure of the flaps. Antivir Ther. 2001;6 Suppl 1:52.[PubMed][Google Scholar]
41. Winters M, Merigan TVariants other than aspartic acid at codon 69 of the HIV type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs. Antimicrob Agents Chemother. 2001;45:2276–2279.[Google Scholar]